Loading...
Loading...
Goldman Sachs remains Neutral-rated with a $38 target price on Health Net
HNT following broadly in-line results for 4Q.
Goldman Sachs notes, "Following 4Q results that were broadly in line with our estimates (4Q operating EPS was $0.90 vs. our $0.89), we tweak our 2012-14 EPS estimates upwards as the better than expected start to the 2012 Medicare Advantage enrollment season flows through our model. We maintain our recently introduced 2014 EPS at $4.56, implying 16% yoy EPS growth, reflecting strong top-line growth from dual-eligible conversion and reform coverage expansion, partly offset by commercial and Medicare margin contraction."
HNT closed at $36.48 a share on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in